Alzheimer’s Precision Neurology: Epigenetics of Cytochrome P450 Genes in Circulating Cell-Free DNA for Disease Prediction and Mechanism

Precision neurology combines high-throughput technologies and statistical modeling to identify novel disease pathways and predictive biomarkers in Alzheimer’s disease (AD). Brain cytochrome P450 (CYP) genes are major regulators of cholesterol, sex hormone, and xenobiotic metabolism, and they could play important roles in neurodegenerative disorders. Increasing evidence suggests that epigenetic factors contribute to AD development. We evaluated cytosine (‘CpG’)-based DNA methylation changes in AD using circulating cell-free DNA (cfDNA), to which neuronal cells are known to contribute. We investigated CYP-based mechanisms for AD pathogenesis and epigenetic biomarkers for disease detection. We performed a case–control study using 25 patients with AD and 23 cognitively healthy controls using the cfDNA of CYP genes. We performed a logistic regression analysis using the MetaboAnalyst software computer program and a molecular pathway analysis based on epigenetically altered CYP genes using the Cytoscape program. We identified 130 significantly (false discovery rate correction q-value < 0.05) differentially methylated CpG sites within the CYP genes. The top two differentially methylated genes identified were CYP51A1 and CYP2S1. The significant molecular pathways that were perturbed in AD cfDNA were (i) androgen and estrogen biosynthesis and metabolism, (ii) C21 steroid hormone biosynthesis and metabolism, and (iii) arachidonic acid metabolism. Existing evidence suggests a potential role of each of these biochemical pathways in AD pathogenesis. Next, we randomly divided the study group into discovery and validation sub-sets, each consisting of patients with AD and control patients. Regression models for AD prediction based on CYP CpG methylation markers were developed in the discovery or training group and tested in the independent validation group. The CYP biomarkers achieved a high predictive accuracy. After a 10-fold cross-validation, the combination of cg17852385/cg23101118 + cg14355428/cg22536554 achieved an AUC (95% CI) of 0.928 (0.787~1.00), with 100% sensitivity and 92.3% specificity for AD detection in the discovery group. The performance remained high in the independent validation or test group, achieving an AUC (95% CI) of 0.942 (0.905~0.979) with a 90% sensitivity and specificity. Our findings suggest that the epigenetic modification of CYP genes may play an important role in AD pathogenesis and that circulating CYP-based cfDNA biomarkers have the potential to accurately and non-invasively detect AD.

[1]  A. Klochendler,et al.  A DNA methylation atlas of normal human cell types , 2023, Nature.

[2]  Yousef Rasmi,et al.  The role of DNA methylation in progression of neurological disorders and neurodegenerative diseases as well as the prospect of using DNA methylation inhibitors as therapeutic agents for such disorders , 2022, IBRO neuroscience reports.

[3]  E. Ballestar,et al.  Circulating cell-free DNA methylation mirrors alterations in cerebral patterns in epilepsy , 2022, Clinical Epigenetics.

[4]  A. Gross,et al.  Circulating Cell-Free Genomic DNA Is Associated with an Increased Risk of Dementia and with Change in Cognitive and Physical Function. , 2022, Journal of Alzheimer's disease : JAD.

[5]  S. Sadigh-Eteghad,et al.  Pharmacotherapy of Alzheimer’s disease: an overview of systematic reviews , 2022, European Journal of Clinical Pharmacology.

[6]  J. Xia,et al.  Using MetaboAnalyst 5.0 for LC–HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data , 2022, Nature Protocols.

[7]  W. Berrettini,et al.  Artificial Intelligence and Circulating Cell-Free DNA Methylation Profiling: Mechanism and Detection of Alzheimer’s Disease , 2022, Cells.

[8]  J. Mill,et al.  DNA methylation signatures of Alzheimer’s disease neuropathology in the cortex are primarily driven by variation in non-neuronal cell-types , 2022, bioRxiv.

[9]  Shengying Qin,et al.  Cytochrome P450 Enzymes and Drug Metabolism in Humans , 2021, International journal of molecular sciences.

[10]  S. Mueller,et al.  Epigenetics Is Implicated in the Basis of Gender Incongruence: An Epigenome-Wide Association Analysis , 2021, Frontiers in Neuroscience.

[11]  Ronita Nag Chaudhuri,et al.  DNA methylation and regulation of gene expression: Guardian of our health , 2021, The Nucleus.

[12]  Rik van der Kant,et al.  Cholesterol and Alzheimer’s Disease; From Risk Genes to Pathological Effects , 2021, Frontiers in Aging Neuroscience.

[13]  D. Bennett,et al.  Abnormal brain cholesterol homeostasis in Alzheimer’s disease—a targeted metabolomic and transcriptomic study , 2021, npj Aging and Mechanisms of Disease.

[14]  D. Carey,et al.  Artificial intelligence and leukocyte epigenomics: Evaluation and prediction of late-onset Alzheimer’s disease , 2021, PloS one.

[15]  Chadwick M. Hales,et al.  Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase and ethanolamides metabolism with Alzheimer's disease , 2021, medRxiv.

[16]  Hua Yu,et al.  Cell-Free DNA: Hope and Potential Application in Cancer , 2021, Frontiers in Cell and Developmental Biology.

[17]  W. Daniel,et al.  Cytochrome P450 expression and regulation in the brain , 2020, Drug metabolism reviews.

[18]  R. Blesa,et al.  The Therapeutic Potential of Epigenetic Modifications in Alzheimer’s Disease , 2020, Alzheimer’s Disease: Drug Discovery.

[19]  R. Lahesmaa,et al.  Plasma cell-free DNA methylation marks for episodic memory impairment: a pilot twin study , 2020, Scientific Reports.

[20]  Y. Akwa Steroids and Alzheimer’s Disease: Changes Associated with Pathology and Therapeutic Potential , 2020, International journal of molecular sciences.

[21]  A. Fonteh,et al.  Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies , 2020, Frontiers in Physiology.

[22]  R. Cacabelos Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia , 2020, International journal of molecular sciences.

[23]  A. Kalmár,et al.  Blood Collection and Cell-Free DNA Isolation Methods Influence the Sensitivity of Liquid Biopsy Analysis for Colorectal Cancer Detection , 2019, Pathology & Oncology Research.

[24]  A. Labarga,et al.  DNA methylation signature of human hippocampus in Alzheimer’s disease is linked to neurogenesis , 2019, Clinical Epigenetics.

[25]  C. W. Tam,et al.  Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer’s Disease , 2019, American journal of Alzheimer's disease and other dementias.

[26]  T. Peretz,et al.  Life and death of circulating cell-free DNA , 2019, Cancer biology & therapy.

[27]  J. Olivier,et al.  Dietary arachidonic acid: a Janus face actor in brain and Alzheimer’s disease? , 2018, OCL.

[28]  Olaf Sporns,et al.  Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. , 2018, Journal of Alzheimer's disease : JAD.

[29]  J. J. Espinosa-Aguirre,et al.  Cytochrome P450 in the central nervous system as a therapeutic target in neurodegenerative diseases , 2018, Drug metabolism reviews.

[30]  D. Bennett,et al.  CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem , 2018, Neurology: Genetics.

[31]  Strasbourg,et al.  Arachidonic acid in Alzheimer's disease , 2016 .

[32]  Timothy Hardy,et al.  Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease , 2016, Gut.

[33]  Henrik Zetterberg,et al.  Identification of tissue-specific cell death using methylation patterns of circulating DNA , 2016, Proceedings of the National Academy of Sciences.

[34]  Hee-Yong Kim,et al.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism. , 2015, Biochimica et biophysica acta.

[35]  R. Cacabelos,et al.  Personalized Medicine of Alzheimer’s Disease , 2014, Handbook of Pharmacogenomics and Stratified Medicine.

[36]  N. Zawia,et al.  Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease. , 2013, Pharmacology & therapeutics.

[37]  Walter L. Miller,et al.  Human cytochromes P450 in health and disease , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.

[38]  C. Pike,et al.  Gender, sex steroid hormones, and Alzheimer's disease , 2013, Hormones and Behavior.

[39]  D. Wishart,et al.  Translational biomarker discovery in clinical metabolomics: an introductory tutorial , 2012, Metabolomics.

[40]  David S. Wishart,et al.  MetaboAnalyst 2.0—a comprehensive server for metabolomic data analysis , 2012, Nucleic Acids Res..

[41]  Giovanni Scardoni,et al.  Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data , 2012, Bioinform..

[42]  U. Schwarz,et al.  Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study. , 2011, The American journal of geriatric pharmacotherapy.

[43]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[44]  J. Gustafsson,et al.  Cytochrome P450 in the brain; a review. , 2001, Current drug metabolism.

[45]  R. Tyndale,et al.  Cytochrome P450 enzymes and metabolism of drugs and neurotoxins within the mammalian brain. , 2022, Advances in Pharmacology.

[46]  M. Mielke Sex and Gender Differences in Alzheimer's Disease Dementia. , 2018, The Psychiatric times.

[47]  R. Tibshirani Regression Shrinkage and Selection via the Lasso , 1996 .